Metabolism of remimazolam in primary human hepatocytes during continuous long-term infusion in a 3-D bioreactor system

BACKGROUND: Remimazolam is an ultra-short acting benzodiazepine under development for procedural sedation and general anesthesia. It is hydrolyzed by CES1 to an inactive metabolite (CNS7054). PURPOSE: In this study, the effect of continuous remimazolam exposure on its metabolism and on CES1 expressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Freyer, Nora, Knöspel, Fanny, Damm, Georg, Greuel, Selina, Schneider, Christin, Seehofer, Daniel, Stöhr, Thomas, Petersen, Karl-Uwe, Zeilinger, Katrin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450186/
https://www.ncbi.nlm.nih.gov/pubmed/31037028
http://dx.doi.org/10.2147/DDDT.S186759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450186/
https://www.ncbi.nlm.nih.gov/pubmed/31037028
http://dx.doi.org/10.2147/DDDT.S186759

Ejemplares similares